Efficacy vs. Adverse Effects: Which Trumps? Point-Counterpoint

Log in for full access to this session if you are registered.

Registration Options

Efficacy vs. Adverse Effects: Which Trumps? Point-Counterpoint ~ Member Rate - $40.00
Efficacy vs. Adverse Effects: Which Trumps? Point-Counterpoint ~ Non-Member Rate - $50.00

Session Summary

Although first generation antipsychotics (FGAs) provided the bedrock of clinical treatment for people with schizophrenia for over 30 years, the advent of successive new drugs- second generation antipsychotics (SGAs)- led to a decline in use of FGAs in favor of SGAs that were (at least initially) perceived as both more efficacious and better tolerated.  While the relative merits of FGAs and SGAs remain hotly debated, it is now clear that the selection of an appropriate antipsychotic for any given patient represents a highly complex clinical decision-making process.

Personalized medicine remains some distance off currently for schizophrenia.  Additionally, federal policy and Institute of Medicine consensus collectively call for a more rapid translation of basic and clinical research findings into service delivery, a real gap currently in the treatment of schizophrenia.  Against that complex background, this session will tease out our current status with respect to the key clinical goal of seeking for each patient, the optimum balance between (high) efficacy and (high) tolerability in the context of pharmacotherapy with FGAs and SGAs.

The purpose and debate format of this symposium is consistent with this and seeks to provide attendees with a lively and interactive appreciation of the current psychopharmacology of schizophrenia.  Dr Nasrallah and Dr Buckley will pit themselves for/against sides on components of Efficacy (depressive symptoms, cognition, etc.) and side effects (TD, etc.) and will cover a spectrum of germane issues, also seeking out at the end of each section the input of the audience. This will be a highly interactive session, covering key aspects of psychopharmacology of current and emerging importance in schizophrenia.

Registrant Resources

Sorry, but you are not an authorized user. Please register for the course at the top of this page.

Faculty Information

Peter Buckley, MD
Henry Nasrallah, MD

View biographical information and disclosures

Learning Objectives

  1. Identify the available literature regarding and differentiate the relative efficacy of typical and atypical antipsychotics used in patients with schizophrenia during the acute and maintenance phases of treatment.
  2. Identify the available literature regarding and differentiate the relative tolerability profiles of typical and atypical antipsychotics used in patients with schizophrenia during the acute and maintenance phases of treatment (considering morbidity and mortality, cost, and patient preference).
  3. Compare and contrast the risk-benefit ratio of typical and atypical antipsychotics in the treatment of schizophrenia.
  4. Discuss the importance of efficacy versus tolerability in the clinical decision making process for the individualized treatment of schizophrenia during the acute and maintenance phases.

Continuing Education Credit

Activity Dates: 04/20/2010 - 04/20/2013
ACPE Contact Hours: 2.0
ACPE Number: 0284-0000-10-012-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE and ACCME credit is accepted for certification renewal.

Course Requirements

This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.

Participants in this course must complete an examination and achieve a score of 60% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.

Target Audience

If you are a pharmacist, nurse practitioner or other healthcare professional involved in the medication therapy management of psychiatric and/or neurological patients, we invite you to participate in this online course.

Grant Support

This programming was supported in part by grants from Bristol-Myers Squibb, Otsuka America Pharmaceutical, Inc., Lilly USA, LLC, AstraZeneca and Cyberonics.